Search

Displaying results 921 - 930 of 1279 in total
  1. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dos...

  2. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It i...

  3. Drug

    ssCART-19 cells

    go.drugbank.com/drugs/DB18653
    Investigational

    ssCART-19 cells consist of autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6).

    Synonyms: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
  4. Drug

    Rotigotine

    go.drugbank.com/drugs/DB05271
    ApprovedInvestigational

    However, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008.

  5. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it.

  6. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    [L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention

  7. Drug

    Omidenepag isopropyl

    go.drugbank.com/drugs/DB15071
    Approved

    [A253263,A253268] Prostanoid FP receptor agonists (FP agonists), such as [latanoprost], are part of the first-line therapy for ocular hypertension and primary open-angle glaucoma; however, not all patients

  8. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives ca...

  9. Drug

    Latanoprost

    go.drugbank.com/drugs/DB00654
    ApprovedInvestigational

    Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for gl...

    Mixtures: Tim-Lat -PF, Tim-Dor-Lat
  10. Drug

    Octopamine

    go.drugbank.com/drugs/DB13251
    Experimental

    It has been used as a nootropic, and therefore it and all of its enantiomer are prohibited by the World Anti-doping Agency (WADA) as of 2014.